Background Background The unavailability of
The unavailability of psychotropic and analgesic drugs for psychotropic and analgesic drugs for medical purposes results in suffering that medical purposes results in suffering that goes unrelieved.Their excessive goes unrelieved.Their excessive availability results in overmedication and availability results in overmedication and suffering of a different kind. suffering of a different kind.
Aims Aims To highlight the discrepancies
To highlight the discrepancies between the demand for and supply of between the demand for and supply of controlled drugs for licit purposes by controlled drugs for licit purposes by different communities, and to promote different communities, and to promote their rational utilisation. their rational utilisation.
Method Method Review of the United Nations,
Review of the United Nations, World Health Organization and other World Health Organization and other literature on the licit use of narcotic literature on the licit use of narcotic analgesics and psychotropic substances. analgesics and psychotropic substances.
Results

There are large differences in
There are large differencesin the use of psychotropics and analgesics by the use of psychotropics and analgesics by different countries.The differences different countries.The differences between industrialised and nonbetween industrialised and nonindustrialised countries are particularly industrialised countries are particularly striking.Thereis evidence of unmet needin striking.Thereis evidence of unmet needin some countries and overutilisation in some countries and overutilisation in others. others.
Conclusions
Conclusions Governments, Governments, international organisations, health international organisations, health professionals and the pharmaceutical professionals and the pharmaceutical industry must work together to ensure an industry must work together to ensure an adequate supply of psychotropic and adequate supply of psychotropic and analgesic drugs for medical and scientific analgesic drugs for medical and scientific purposes, and to implement appropriate purposes, and to implement appropriate measures to minimise the development of measures to minimise the development of misuse and dependence. misuse and dependence.
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Although biological methods of treatment Although biological methods of treatment for mental illnesses were available before for mental illnesses were available before the Second World War, it was not until the Second World War, it was not until the 1950s that effective and safe psychothe 1950s that effective and safe psychoactive drugs became available. As a active drugs became available. As a consequence of the introduction of consequence of the introduction of chlorpromazine and reserpine, the number chlorpromazine and reserpine, the number of mental hospital in-patients fell markedly, of mental hospital in-patients fell markedly, even though admission rates increased, even though admission rates increased, because length of stay was substantially because length of stay was substantially reduced and patients were increasingly reduced and patients were increasingly managed as out-patients. However, the managed as out-patients. However, the progress made since then -which conprogress made since then -which continues today -should not be perceived tinues today -should not be perceived solely in terms of the number of hospital solely in terms of the number of hospital patients and the economic benefits of outpatients and the economic benefits of outpatient treatment. The very real reduction patient treatment. The very real reduction in human suffering, of patients and their in human suffering, of patients and their families, must never be forgotten. Furtherfamilies, must never be forgotten. Furthermore, the ability to treat mental illness more, the ability to treat mental illness has removed some of the fear of it and the has removed some of the fear of it and the associated stigma (Ghodse & Khan, associated stigma (Ghodse & Khan, 1988) . Since then, there has been huge 1988). Since then, there has been huge progress and an explosion in the drugs progress and an explosion in the drugs available to us. In much of the world, this available to us. In much of the world, this has been accompanied by growing concern has been accompanied by growing concern about what is perceived as their excessive about what is perceived as their excessive use, although there are also parts of use, although there are also parts of the world where suffering goes largely the world where suffering goes largely unrelieved. unrelieved.
Background Background
There are five principal symptoms for There are five principal symptoms for which psychoactive drugs are commonly which psychoactive drugs are commonly prescribed -inability to cope, depression, prescribed -inability to cope, depression, anxiety, sleeplessness and pain -and they anxiety, sleeplessness and pain -and they have a number of features in common: they have a number of features in common: they are all symptoms that everyone has experiare all symptoms that everyone has experienced at some time or other; the point at enced at some time or other; the point at which they are regarded as sufficiently which they are regarded as sufficiently severe to warrant medical intervention severe to warrant medical intervention and treatment is somewhat arbitrary and and treatment is somewhat arbitrary and varies from one country to another; they varies from one country to another; they are concomitants of other symptoms and are concomitants of other symptoms and may arise as a consequence of them (e.g. may arise as a consequence of them (e.g. an individual patient may be anxious an individual patient may be anxious because of a lump and may be unable to because of a lump and may be unable to sleep because of being in pain -so it is sleep because of being in pain -so it is difficult to disentangle any one symptom difficult to disentangle any one symptom from the much wider range of symptoms from the much wider range of symptoms from which the patient is suffering confrom which the patient is suffering concurrently); and they are all normal and currently); and they are all normal and reasonable responses to common situations reasonable responses to common situations and, even when they are severe, may still and, even when they are severe, may still be reasonable responses to very difficult be reasonable responses to very difficult situations. situations. Although these symptoms are familiar Although these symptoms are familiar and common occurrences, the scale of the and common occurrences, the scale of the associated suffering for the world as a associated suffering for the world as a whole still comes as something of a shock whole still comes as something of a shock because it is so huge. For example, an estibecause it is so huge. For example, an estimated 450 million people alive today suffer mated 450 million people alive today suffer from some form of mental or brain disfrom some form of mental or brain disorder, including alcohol and substance use order, including alcohol and substance use disorders, with 121 million suffering from disorders, with 121 million suffering from depression. Projections suggest that the depression. Projections suggest that the proportion of the global burden of disease proportion of the global burden of disease attributable to mental and brain disorders attributable to mental and brain disorders will rise to 15% by the year 2020. At a will rise to 15% by the year 2020. At a more homely level, these huge figures transmore homely level, these huge figures translate into the fact that one in four families late into the fact that one in four families has at least one family member who is afhas at least one family member who is affected by mental or brain disorder (World fected by mental or brain disorder (World Health Organization, 2001 Health Organization, 2001a World Health ; World Health Assembly, 2002) . Assembly, 2002) .
The costs of mental disorders are The costs of mental disorders are correspondingly huge in terms of health correspondingly huge in terms of health care costs and loss of productivity at home care costs and loss of productivity at home and in the workplace. For example, just in and in the workplace. For example, just in the UK aggregate costs of mental illness the UK aggregate costs of mental illness have been estimated to be £32 billion, with have been estimated to be £32 billion, with reduced ability to work and associated reduced ability to work and associated productivity losses accounting for about productivity losses accounting for about 45% of this sum (World Health Assembly, 45% of this sum (World Health Assembly, 2002 ). 2002 .
Fortunately, today there are effective Fortunately, today there are effective medications and psychosocial interventions medications and psychosocial interventions to treat mental disorders and pain. to treat mental disorders and pain. Although these are within the reach of all Although these are within the reach of all countries and are widely used, there is a countries and are widely used, there is a global shortage of resources for mental global shortage of resources for mental health, which results in stark disparities in health, which results in stark disparities in the provision of care. the provision of care.
These disparities are illustrated by a These disparities are illustrated by a World Health Organization study of World Health Organization study of mental health resources (ATLAS; Abuse mental health resources (ATLAS; Abuse Trends Linkage Alerting System), which Trends Linkage Alerting System), which collected information from 185 countries collected information from 185 countries (World Health Organization, 2001 (World Health Organization, 2001b (World Health Organization, 1996) and there is a broad Organization, 1996) and there is a broad consensus that, for the treatment of such consensus that, for the treatment of such pain, opioids (specifically morphine) are inpain, opioids (specifically morphine) are indispensable because of their affordability dispensable because of their affordability and analgesic efficacy. Research conducted and analgesic efficacy. Research conducted in several countries has shown that opioid in several countries has shown that opioid treatment can be effective in 75-90% of treatment can be effective in 75-90% of patients with cancer-related pain, and of patients with cancer-related pain, and of course opioids are also used to relieve acute course opioids are also used to relieve acute or chronic pain not related to cancer or chronic pain not related to cancer (World Health Organization, 1986) . In- (World Health Organization, 1986) . Indeed, long-term, persistent and debilitating deed, long-term, persistent and debilitating pain is a major public health problem, pain is a major public health problem, accounting for untold suffering and lost accounting for untold suffering and lost productivity (Gureje productivity (Gureje et al et al, 1998; World , 1998; World Health Organization, 2001 Health Organization, 2001a a). ).
As one of the oldest drugs known to As one of the oldest drugs known to man, and with credentials as an analgesic man, and with credentials as an analgesic stretching over hundreds of years, one stretching over hundreds of years, one might expect morphine and similar drugs might expect morphine and similar drugs to be used universally for the treatment of to be used universally for the treatment of pain. In one sense it is widely used and, in pain. In one sense it is widely used and, in addition to morphine, a variety of semiaddition to morphine, a variety of semisynthetic and synthetic opioids have been synthetic and synthetic opioids have been developed in an attempt to improve on developed in an attempt to improve on the well-established therapeutic qualities the well-established therapeutic qualities of morphine by separating its desirable of morphine by separating its desirable properties -analgesic, cough suppressant, properties -analgesic, cough suppressant, anti-diarrhoeal -from its undesirable, anti-diarrhoeal -from its undesirable, addictive properties. addictive properties.
Unfortunately North America, with 7% of the world's North America, with 7% of the world's population, consumes 47% of the total population, consumes 47% of the total world's supply of morphine, and Europe, world's supply of morphine, and Europe, with 12% of the world's population, uses with 12% of the world's population, uses a further 37%. Africa, on the other hand, a further 37%. Africa, on the other hand, which has 13% of the world's population, which has 13% of the world's population, uses only 1% of the world's licit supply of uses only 1% of the world's licit supply of morphine. The same situation pertains in morphine. The same situation pertains in relation to the collective use of the main relation to the collective use of the main narcotic drugs, with the USA by far the narcotic drugs, with the USA by far the largest consumer (Fig. 2 ). There are similar largest consumer (Fig. 2 ). There are similar disparities within Europe, with the wealthy disparities within Europe, with the wealthy countries of Western Europe consuming far countries of Western Europe consuming far higher quantities of opioid analgesics than higher quantities of opioid analgesics than their neighbours in Eastern Europe. Intertheir neighbours in Eastern Europe. Interestingly, it is the Nordic countries, with estingly, it is the Nordic countries, with only 3% of the European population, only 3% of the European population, whose level of consumption seems partiwhose level of consumption seems particularly high. From such statistics it can be cularly high. From such statistics it can be demonstrated that the ten largest opioiddemonstrated that the ten largest opioidconsuming countries in the world account consuming countries in the world account for as much as 80% of morphine consumpfor as much as 80% of morphine consumption (International Narcotics Control tion (International Narcotics Control Board, 2000 , 2002 Board, 2000 , 2002a . ).
In terms of individual consumption, the In terms of individual consumption, the average per capita consumption of average per capita consumption of morphine in 1998 in the ten countries with morphine in 1998 in the ten countries with the highest consumption levels was 31 g per the highest consumption levels was 31 g per 1000 inhabitants. In the ten countries with 1000 inhabitants. In the ten countries with the next highest consumption levels, the the next highest consumption levels, the corresponding figure was 16 g per 1000 corresponding figure was 16 g per 1000 inhabitants. In the next 60 countries with inhabitants. In the next 60 countries with a total morphine consumption of more than a total morphine consumption of more than 1 kg, it was only 2 g per 1000 inhabitants. 1 kg, it was only 2 g per 1000 inhabitants. In the remaining 120 countries, there was In the remaining 120 countries, there was little or no opioid consumption, with little or no opioid consumption, with several African countries reporting no several African countries reporting no morphine consumption at all. In a few morphine consumption at all. In a few countries there is now a small improvement countries there is now a small improvement because they have recently initiated probecause they have recently initiated programmes for the relief of cancer pain, but grammes for the relief of cancer pain, but there has been no such improvement in there has been no such improvement in most developing countries (International most developing countries (International Narcotics Control Board, 2000) . Narcotics Control Board, 2000) .
In a world where the excessive use of In a world where the excessive use of controlled drugs tends to dominate discontrolled drugs tends to dominate discussions, the lack of such drugs receives cussions, the lack of such drugs receives comparatively little attention. However, comparatively little attention. However, the most frequently mentioned causes of the most frequently mentioned causes of 1 6 1 6 inadequate availability of opioid drugs are: inadequate availability of opioid drugs are: restrictive regulations and cumbersome restrictive regulations and cumbersome administrative procedures; concerns about administrative procedures; concerns about diversion and the consequences of inadverdiversion and the consequences of inadvertent errors; concerns about iatrogenic tent errors; concerns about iatrogenic addiction; and inadequate or insufficient addiction; and inadequate or insufficient training of health personnel. Clearly, there training of health personnel. Clearly, there are issues here that must be addressed both are issues here that must be addressed both by the governments concerned and by the by the governments concerned and by the medical profession but, in the interim, the medical profession but, in the interim, the net result is that only 10-30% of patients net result is that only 10-30% of patients suffering from severe cancer-related pain suffering from severe cancer-related pain may be receiving adequate treatment even may be receiving adequate treatment even in many technologically advanced counin many technologically advanced countries, with an even lower rate in developing tries, with an even lower rate in developing countries (Bonica, 1985 ; World Health countries (Bonica, 1985; World Health Organization, 1986 , 1993 , 2000 InterOrganization, 1986 InterOrganization, , 1993 InterOrganization, , 2000 International Narcotics Control Board, 2000) . national Narcotics Control Board, 2000). Although non-opioid, or indeed nonAlthough non-opioid, or indeed nonpharmacological, interventions may be pharmacological, interventions may be utilised for a proportion of cases, it is utilised for a proportion of cases, it is widely acknowledged that severe pain rewidely acknowledged that severe pain requires opioids and, according to the World quires opioids and, according to the World Health Organization Expert Committee Health Organization Expert Committee and other reports, the worldwide medical and other reports, the worldwide medical need for opioids is not being fully met, parneed for opioids is not being fully met, particularly in relation to patients with cancer ticularly in relation to patients with cancer who may require large doses of opioids to who may require large doses of opioids to obtain optimal pain relief (Twycross & obtain optimal pain relief (Twycross & Lack, 1984; Joranson, 1993; World Health Lack, 1984; Joranson, 1993; World Health Organization, 1993) . Because the manufacOrganization, 1993). Because the manufacture, import and export of opioids are ture, import and export of opioids are highly regulated both nationally and interhighly regulated both nationally and internationally, it is unlikely that populations nationally, it is unlikely that populations within countries reporting very low statiswithin countries reporting very low statistics in all of these areas have easy access tics in all of these areas have easy access to these drugs. It is similarly unlikely that to these drugs. It is similarly unlikely that large quantities of illicit large quantities of illicit opioids are opioids are available for analgesic purposes in these very available for analgesic purposes in these very poor countries, when such big profits can be poor countries, when such big profits can be made from the illicit market in more affluent made from the illicit market in more affluent countries. 2001 , 2002 Narcotics Control Board, 2001 , 2002b . ).
When consumption is measured in When consumption is measured in terms of the number of defined daily doses terms of the number of defined daily doses (DDDs) per 1000 individuals per day, these (DDDs) per 1000 individuals per day, these international differences are immediately international differences are immediately 17 17 (Fig. 5) . The figures for consumption of (Fig. 5) . The figures for consumption of anxiolytics, as measured by DDDs during anxiolytics, as measured by DDDs during the same period, were also disproportional: the same period, were also disproportional:
56 DDDs per 1000 inhabitants per day in 56 DDDs per 1000 inhabitants per day in Europe, 23 in the Americas, 15 in Asia, 7 Europe, 23 in the Americas, 15 in Asia, 7 in Oceania and 5 in Africa, confirming that in Oceania and 5 in Africa, confirming that the differences are real and not due to inthe differences are real and not due to inconsistencies in how use is reported consistencies in how use is reported (Fig. 6 ) (International Narcotics Control (Fig. 6) (International Narcotics Control Board, 2001 , 2002 Board, 2001 , 2002b . ).
AVAILABILITY OF DRUGS AVAILABILITY OF DRUGS AND ACCESS AND ACCESS
Stepping back from these comparisons for Stepping back from these comparisons for a moment, it is worth remembering that a moment, it is worth remembering that during the past several decades the availduring the past several decades the availability of increasingly effective, safe theraability of increasingly effective, safe therapeutic agents has made an important peutic agents has made an important contribution to improving health care contribution to improving health care throughout the world. The development throughout the world. The development of better medicines combined with better of better medicines combined with better management of their availability could, management of their availability could, and should, make the relief of pain and and should, make the relief of pain and suffering more universally available as suffering more universally available as well as qualitatively well as qualitatively better. Unfortunately, better. Unfortunately, there are shortfalls in availability and there are shortfalls in availability and there is evidence that in there is evidence that in many countries many countries these drugs do not necessarily reach those these drugs do not necessarily reach those who need them most. who need them most.
At the same time, excessive -someAt the same time, excessive -sometimes apparently unlimited -availability times apparently unlimited -availability of addictive medicines on national or interof addictive medicines on national or international markets is as much a cause of national markets is as much a cause of concern as insufficient supplies. Although concern as insufficient supplies. Although the unavailability of medicines deprives the unavailability of medicines deprives patients of their fundamental right to, and patients of their fundamental right to, and opportunities for, relief of pain and opportunities for, relief of pain and suffering, the excessive availability of such suffering, the excessive availability of such medicines frequently results in unjustified medicines frequently results in unjustified overconsumption and dependence. It overconsumption and dependence. It may also lead to the diversion of such may also lead to the diversion of such drugs to drugs to illicit trafficking and drug misuse illicit trafficking and drug misuse (United Nations, 1991; World Health (United Nations, 1991; World Health Organization, 2001 Organization, 2001a a). ).
Assessing the medical need for drugs Assessing the medical need for drugs and ensuring sufficient but not excessive and ensuring sufficient but not excessive supplies is therefore important. Unfortusupplies is therefore important. Unfortunately, most developing countries lack the nately, most developing countries lack the necessary resources and expertise and the necessary resources and expertise and the problem is compounded because there is problem is compounded because there is no universal consumption standard that is no universal consumption standard that is applicable to all countries regardless of applicable to all countries regardless of their social, demographic and economic their social, demographic and economic situations. What constitutes optimum availsituations. What constitutes optimum availability in one country may not be optimal ability in one country may not be optimal in another. Furthermore, there is no in another. Furthermore, there is no country or region in which the status of country or region in which the status of the availability of a medicine can be considthe availability of a medicine can be considered as a standard for the rest of the world. ered as a standard for the rest of the world.
For developed countries, the most For developed countries, the most immediate problems are predominantly immediate problems are predominantly 1 8 1 8 related to overconsumption. This is a trend related to overconsumption. This is a trend that can be observed in many parts of the that can be observed in many parts of the world, particularly in technologically adworld, particularly in technologically advanced countries, but is not restricted to vanced countries, but is not restricted to them. Excessive drug consumption that is them. Excessive drug consumption that is medically unjustified has a number of genermedically unjustified has a number of general and sometimes country-specific causes al and sometimes country-specific causes and driving forces, of which the most signifand driving forces, of which the most significant are the commercial, sociocultural and icant are the commercial, sociocultural and educational environments in those couneducational environments in those countries. For example, newly gained wealth or tries. For example, newly gained wealth or affluence appears to be the origin of quickly affluence appears to be the origin of quickly growing drug consumption in countries growing drug consumption in countries experiencing rapid economic growth, experiencing rapid economic growth, especially if such consumption is perceived especially if such consumption is perceived to be part of a new fashion. to be part of a new fashion. One of the features of developed One of the features of developed countries is an increasing consumption of countries is an increasing consumption of sedative hypnotics for the treatment of sedative hypnotics for the treatment of anxiety and insomnia. It is not clear anxiety and insomnia. It is not clear whether this reflects a true increase in the whether this reflects a true increase in the prevalence of these conditions but some prevalence of these conditions but some surveys show that clinically significant surveys show that clinically significant anxiety affects up to 15% of the population anxiety affects up to 15% of the population (Regier (Regier et al et al, 1988; Tohen & Bromet, , 1988; Tohen & Bromet, 2000; International Narcotics Control 2000; International Narcotics Control Board, 2001) . In part, this can be attributed Board, 2001) . In part, this can be attributed to the growing population of older people, to the growing population of older people, who are the main consumers of these who are the main consumers of these classes of drugs. Demographic change, classes of drugs. Demographic change, therefore, may be a significant factor therefore, may be a significant factor contributing to growing psychotropic contributing to growing psychotropic consumption in many countries. consumption in many countries.
Other conditions too are increasing in Other conditions too are increasing in prevalence and are demanding a pharmacoprevalence and are demanding a pharmacological solution. Obesity is one such condilogical solution. Obesity is one such condition and it appears to be spreading at such a tion and it appears to be spreading at such a rate that it is now often referred to as an rate that it is now often referred to as an epidemic -and with prevalence rates as epidemic -and with prevalence rates as high as 30%, this does not appear to be high as 30%, this does not appear to be an overstatement of the problem (Bjornan overstatement of the problem (Bjorntorp, 1997; Rosenbaum torp, 1997; Rosenbaum et al et al, 1997; Inter-, 1997; International Narcotics Control Board, 2001) . national Narcotics Control Board, 2001) . Its treatment increasingly involves the use Its treatment increasingly involves the use of anorectic drugs, many of which are of anorectic drugs, many of which are amphetamine-type stimulants or are closely amphetamine-type stimulants or are closely related to these drugs. related to these drugs.
As well as obesity there is growing awareAs well as obesity there is growing awareness and diagnosis of attention-deficit hyperness and diagnosis of attention-deficit hyperactivity disorder (ADHD), which is also activity disorder (ADHD), which is also treated symptomatically with stimulants, treated symptomatically with stimulants, mostly methylphenidate. These two factors mostly methylphenidate. These two factors together account for the fact that the USA together account for the fact that the USA consumes far greater quantities of stimulants consumes far greater quantities of stimulants than other countries (Ghodse, 1999) . than other countries (Ghodse, 1999) .
In addition to these conditions, a conIn addition to these conditions, a considerable proportion of patients is also siderable proportion of patients is also reported to be suffering from personal, reported to be suffering from personal, interpersonal and social problems rather interpersonal and social problems rather than from real mental or physical disease. than from real mental or physical disease.
Indeed, in some countries as many as Indeed, in some countries as many as 25-35% of all patients were prescribed 25-35% of all patients were prescribed psychotropic drugs without being psychotropic drugs without being diagnosed as having a mental disorder diagnosed as having a mental disorder (Fombonne (Fombonne et al et al, 1989) . , 1989). In view of the underlying conditions In view of the underlying conditions for which psychotropic substances are for which psychotropic substances are being prescribed, it is perhaps not surprisbeing prescribed, it is perhaps not surprising that there is an increasing tendency ing that there is an increasing tendency towards extended periods of use, with towards extended periods of use, with some individuals taking them for more some individuals taking them for more than one year and some taking them more than one year and some taking them more or less indefinitely. Indeed, it has been esor less indefinitely. Indeed, it has been estimated that up to 4% of the population timated that up to 4% of the population of many developed countries are regular of many developed countries are regular long-term consumers of benzodiazepinelong-term consumers of benzodiazepinetype sedative hypnotics (International type sedative hypnotics (International Narcotics Control Board, 2001) . Narcotics Control Board, 2001) .
In one sense there is nothing wrong In one sense there is nothing wrong with long-term treatment -chronic condiwith long-term treatment -chronic conditions usually require chronic treatment. tions usually require chronic treatment. But chronic administration of substances But chronic administration of substances with known dependence potential and/or with known dependence potential and/or other serious side-effects carries its own other serious side-effects carries its own risks that may not outweigh the assumed risks that may not outweigh the assumed benefits of treatment, particularly if there benefits of treatment, particularly if there is no diagnosed mental disorder in the is no diagnosed mental disorder in the first place. Such concerns are heightened first place. Such concerns are heightened when psychotropic substances are prewhen psychotropic substances are prescribed for children. This used to be a scribed for children. This used to be a comparatively rare occurrence but, with comparatively rare occurrence but, with the increased recognition of ADHD, prethe increased recognition of ADHD, prescriptions of methylphenidate to children scriptions of methylphenidate to children have increased very sharply, particularly have increased very sharply, particularly in the USA (Ghodse, 1999) . Although in the USA (Ghodse, 1999). Although not wishing to deny the potential benefit not wishing to deny the potential benefit of treating children with ADHD, it is of treating children with ADHD, it is natural to feel some unease about the natural to feel some unease about the liberal use of a drug with the specific inliberal use of a drug with the specific intention of modifying a child's behaviour tention of modifying a child's behaviour such that he/she becomes more compliant such that he/she becomes more compliant and less troublesome. Furthermore, treatand less troublesome. Furthermore, treatment is initiated in the certain knowledge ment is initiated in the certain knowledge that it will be long-term treatment with a that it will be long-term treatment with a drug with a known dependence potential. drug with a known dependence potential. The need for excellent research, so that The need for excellent research, so that treatment is based on a sound knowledge treatment is based on a sound knowledge base, has never been greater. Similar base, has never been greater. Similar concerns arise in relation to the treatment concerns arise in relation to the treatment of obesity but the fact that the patients of obesity but the fact that the patients are usually adult means that they can are usually adult means that they can participate in the decision-making process participate in the decision-making process and share responsibility for that decision. and share responsibility for that decision.
AT TITUDES AND AT TITUDES AND EXPECTATIONS EXPECTATIONS
Most of the above relates to developed Most of the above relates to developed countries (i.e. those that are technologically countries (i.e. those that are technologically advanced). However, similar tendencies are advanced). However, similar tendencies are now being observed in developing countries now being observed in developing countries and in younger age groups. In other words, and in younger age groups. In other words, correcting mood and behaviour through correcting mood and behaviour through controlled drugs is becoming ever more controlled drugs is becoming ever more widespread. Within this environment of widespread. Within this environment of medicine-taking behaviour and of medimedicine-taking behaviour and of medicine-taking to manage behaviour, an cine-taking to manage behaviour, an expanding self-care culture is also becomexpanding self-care culture is also becoming more socially acceptable. For example, ing more socially acceptable. For example, recent surveys indicate that 70-95% of illrecent surveys indicate that 70-95% of illnesses are managed by self-care in many nesses are managed by self-care in many countries (Fisch, 1979; Vuckovic & countries (Fisch, 1979; Vuckovic & Nichter, 1997) . This tendency has an Nichter, 1997). This tendency has an important influence on medical practice in important influence on medical practice in general and on the clinician-patient general and on the clinician-patient relationship but gives rise to particular relationship but gives rise to particular concern when it involves the long-term concern when it involves the long-term use of psychotropic drugs to treat psychouse of psychotropic drugs to treat psychological reactions to personal and social logical reactions to personal and social problems. problems.
There are also some interesting conThere are also some interesting contrasts in attitudes and expectations. For trasts in attitudes and expectations. For example, the inappropriate use of sedative example, the inappropriate use of sedative drugs by professionals as a 'chemical straitdrugs by professionals as a 'chemical straitjacket' for disturbed, often elderly patients jacket' for disturbed, often elderly patients is rightly condemned by public opinion. is rightly condemned by public opinion. Yet, at the same time, patients' demands Yet, at the same time, patients' demands for the relief of symptoms related to for the relief of symptoms related to personal and social problems may be personal and social problems may be vociferous -not just for themselves but vociferous -not just for themselves but for their child if he/she suffers from ADHD. for their child if he/she suffers from ADHD. Furthermore, self-care using psychotropic Furthermore, self-care using psychotropic substances is often perceived as quite substances is often perceived as quite acceptable and indeed as the legitimate acceptable and indeed as the legitimate and valued involvement of the patient in and valued involvement of the patient in decisions about his/her care. It is these decisions about his/her care. It is these individual and population attitudes toindividual and population attitudes towards the treatment of a range of sympwards the treatment of a range of symptoms that are reflected in the drug toms that are reflected in the drug consumption figures discussed earlier. They consumption figures discussed earlier. They impose a considerable burden on national impose a considerable burden on national economies and infrastructures. For governeconomies and infrastructures. For governments, keeping the supply and consumption ments, keeping the supply and consumption of drugs, especially controlled drugs, in line of drugs, especially controlled drugs, in line with medically justified levels is not only with medically justified levels is not only an important public health issue but an an important public health issue but an economic issue too. economic issue too.
RESPONSIBILITIES OF THE RESPONSIBILITIES OF THE MEDICAL PROFESSION MEDICAL PROFESSION
It is, therefore, worthwhile to consider the It is, therefore, worthwhile to consider the important determinants of the world's important determinants of the world's response to pain, anxiety and human response to pain, anxiety and human suffering, in terms of achieving the approsuffering, in terms of achieving the appropriate availability of the appropriate drugs. priate availability of the appropriate drugs. The medical profession bears enormous reThe medical profession bears enormous responsibility in this area. It is the prescriber sponsibility in this area. It is the prescriber who determines the choice of drug and its who determines the choice of drug and its dosage, duration and termination, and in dosage, duration and termination, and in this process exercises a great deal of profesthis process exercises a great deal of professional freedom and discretion. A wellsional freedom and discretion. A wellfounded therapeutic decision is based on a founded therapeutic decision is based on a good, trusted clinician-patient relationship, good, trusted clinician-patient relationship, accurate assessment and diagnosis by the accurate assessment and diagnosis by the clinician and careful consideration of the clinician and careful consideration of the therapeutic options, including expected therapeutic options, including expected benefits and risks. benefits and risks.
Inappropriate prescription of controlled Inappropriate prescription of controlled psychoactive medicines, which can lead to psychoactive medicines, which can lead to the excessive availability and overconthe excessive availability and overconsumption discussed earlier, includes: uninsumption discussed earlier, includes: uninformed formed prescribing; inconsistent or lax prescribing; inconsistent or lax prescribing; wilful and consistent mispreprescribing; wilful and consistent misprescribing for misuse; self-prescribing and scribing for misuse; self-prescribing and self-administration. The principal underlyself-administration. The principal underlying causes of such behaviour appear to be: ing causes of such behaviour appear to be: inadequate training; shortage of inforinadequate training; shortage of information; lenient or lax attitudes; lack of a mation; lenient or lax attitudes; lack of a sense of professional responsibility; unethisense of professional responsibility; unethical behaviour; personal drug addiction; cal behaviour; personal drug addiction; criminal behaviour or direct financial intercriminal behaviour or direct financial interest. The therapeutic relationship between est. The therapeutic relationship between patient and clinician is also important and patient and clinician is also important and involves responsibilities on the part of both, involves responsibilities on the part of both, but the nature and the extent of these rebut the nature and the extent of these responsibilities are heavily influenced by the sponsibilities are heavily influenced by the culture of the country in question. culture of the country in question.
For all clinicians, however, the aim For all clinicians, however, the aim should be to ensure that drugs are preshould be to ensure that drugs are prescribed only for the condition(s) for which scribed only for the condition(s) for which they have been shown to be effective and they have been shown to be effective and not for any others, and that they are prenot for any others, and that they are prescribed in the correct dosage and for the scribed in the correct dosage and for the correct period of time. Although this correct period of time. Although this may seem self-evident, some of the figures may seem self-evident, some of the figures about drug consumption suggest that it is about drug consumption suggest that it is worthwhile to re-state the obvious. In worthwhile to re-state the obvious. In particular, it is worth emphasising that particular, it is worth emphasising that prescription of the optimum dose is very prescription of the optimum dose is very important. If many patients receive too important. If many patients receive too small or too large a dose, then a high small or too large a dose, then a high proportion of the drug being prescribed proportion of the drug being prescribed is effectively wasted. In contrast, if most is effectively wasted. In contrast, if most patients receive the correct dose of a drug patients receive the correct dose of a drug that has been shown to be efficacious, that has been shown to be efficacious, then the total amount prescribed, even if then the total amount prescribed, even if large, will be used for its intended purlarge, will be used for its intended purpose. Amid concerns about the excessive pose. Amid concerns about the excessive consumption of psychotropic substances, consumption of psychotropic substances, it seems strange that, even in countries it seems strange that, even in countries with well-developed health care systems with well-developed health care systems and good access to psychotropic mediand good access to psychotropic medication, it is estimated that fewer than cation, it is estimated that fewer than 50% of those suffering from depression 50% of those suffering from depression receive treatment. In developing countries, receive treatment. In developing countries, treatment rates for depression may be as treatment rates for depression may be as low as 5% (World Health Assembly, low as 5% (World Health Assembly, 2002) . In addition to lack of resources, 2002). In addition to lack of resources, other obstacles to care include fear, other obstacles to care include fear, lack of information, stigmatisation and lack of information, stigmatisation and discrimination. discrimination.
ROLE OF THE ROLE OF THE PHARMACEUTICAL PHARMACEUTICAL INDUSTRY INDUSTRY
Among other, wider influences on the availAmong other, wider influences on the availability of drugs, the role of the pharmaability of drugs, the role of the pharmaceutical industry and its regulation are ceutical industry and its regulation are clearly significant. Drug manufacture and clearly significant. Drug manufacture and trade are important dynamic sectors of the trade are important dynamic sectors of the global economy subjected to an elaborate global economy subjected to an elaborate international regulatory mechanism for international regulatory mechanism for the protection of consumers. It is worth the protection of consumers. It is worth noting that this requires the collection of noting that this requires the collection of relatively reliable information about drug relatively reliable information about drug consumption worldwide, which forms the consumption worldwide, which forms the basis of the analysis presented here (Ghodse basis of the analysis presented here (Ghodse & Khan, 1988) . & Khan, 1988) .
However, globalisation of the economy, However, globalisation of the economy, to the extent that is now occurring, affects to the extent that is now occurring, affects the capacity of governments to monitor the the capacity of governments to monitor the activities of the pharmaceutical industry. activities of the pharmaceutical industry. The growing intensity and volume of free The growing intensity and volume of free trade and multinational firms operating trade and multinational firms operating across national borders tends to weaken across national borders tends to weaken the power of governments to control trading the power of governments to control trading in and access to drugs, their price and marin and access to drugs, their price and marketing practices. Ultimately, the safeguards keting practices. Ultimately, the safeguards are in the hand of governments. Each partiare in the hand of governments. Each participant in the chain between manufacturer cipant in the chain between manufacturer and consumer has particular interests, opand consumer has particular interests, opportunities and obligations, but the ultimate portunities and obligations, but the ultimate beneficiaries should be the patient and beneficiaries should be the patient and society as a whole. Excessive availability society as a whole. Excessive availability occurs when the relative influence of these occurs when the relative influence of these constituents is out of balance, for example constituents is out of balance, for example as a result of weak government regulation as a result of weak government regulation or unethical or illegal drug promotion. For or unethical or illegal drug promotion. For example, aggressive advertising and marketexample, aggressive advertising and marketing by pharmaceutical firms strongly affects ing by pharmaceutical firms strongly affects prescribing and consuming behaviour and, prescribing and consuming behaviour and, contrary to the provisions of the 1971 contrary to the provisions of the 1971 Convention on Psychotropic Substances Convention on Psychotropic Substances (United Nations, 1971), in some countries (United Nations, 1971) , in some countries such as the USA, some drugs are directly adsuch as the USA, some drugs are directly advertised to the consumer. There is also convertised to the consumer. There is also continuous pressure to reclassify drugs for tinuous pressure to reclassify drugs for 'over-the-counter' sale, which permits them 'over-the-counter' sale, which permits them to be advertised and sold directly to the pubto be advertised and sold directly to the public. In this context it is worth noting that a lic. In this context it is worth noting that a number of over-the-counter medications number of over-the-counter medications are familiar substances of misuse and are familiar substances of misuse and dependence (Ghodse, 2002) . dependence (Ghodse, 2002) .
In summary, it is important that the In summary, it is important that the pharmaceutical industry demonstrates its pharmaceutical industry demonstrates its social responsibility as well as loyalty to social responsibility as well as loyalty to shareholders. It is reasonable to expect it shareholders. It is reasonable to expect it to play its part in curbing excessive to play its part in curbing excessive consumption. Simultaneously, by exerting consumption. Simultaneously, by exerting its influence on determining the price of its influence on determining the price of drugs, many of which are beyond the reach drugs, many of which are beyond the reach of poorer countries, it can ease their of poorer countries, it can ease their availability where they are desperately availability where they are desperately needed. needed.
THE IMPACT OF NEW THE IMPACT OF NEW TECHNOLOGIES TECHNOLOGIES
Electronic communication is a comparaElectronic communication is a comparatively new variable in this scenario. Teletively new variable in this scenario. Telemedicine and internet prescribing may medicine and internet prescribing may greatly facilitate access to medical and greatly facilitate access to medical and pharmaceutical services for large segments pharmaceutical services for large segments of society at lower cost. At the same time, of society at lower cost. At the same time, the potential for error and intentional misthe potential for error and intentional misuse is considerable. Substituting direct use is considerable. Substituting direct doctor-patient contact by electronic comdoctor-patient contact by electronic communication is problematic, particularly in munication is problematic, particularly in relation to the diagnosis of psychiatric disrelation to the diagnosis of psychiatric disorders and the prescription of controlled orders and the prescription of controlled drugs. Efforts to regulate this quickly develdrugs. Efforts to regulate this quickly developing technical area will require close oping technical area will require close cooperation between countries and the cooperation between countries and the relevant international bodies. relevant international bodies.
The internet also provides wide access The internet also provides wide access to a huge amount of health-related inforto a huge amount of health-related information for professionals (clinicians) and mation for professionals (clinicians) and for non-professionals (patients and their for non-professionals (patients and their families). This alters the balance of knowfamilies). This alters the balance of knowledge and power in the therapeutic alliance ledge and power in the therapeutic alliance and therefore changes its very nature. It has and therefore changes its very nature. It has the potential to enhance the patient's role in the potential to enhance the patient's role in the therapeutic alliance, empowering him/ the therapeutic alliance, empowering him/ her to contribute more fully to joint her to contribute more fully to joint decision-making. decision-making.
CONCLUSION CONCLUSION
To summarise, innovations in science and To summarise, innovations in science and pharmaceutical development have gradupharmaceutical development have gradually opened the way for safer, more selecally opened the way for safer, more selective and equally potent medicines for tive and equally potent medicines for alleviating pain and other forms of human alleviating pain and other forms of human suffering. However, there are gross disparisuffering. However, there are gross disparities in the availability of these medicines in ties in the availability of these medicines in different parts of the world and it is clear different parts of the world and it is clear that, for much of the world, much suffering that, for much of the world, much suffering goes untreated. In developed countries, goes untreated. In developed countries, although the assessment of needs is often although the assessment of needs is often based on professional evaluation, actual based on professional evaluation, actual availability tends to be in excess of actual availability tends to be in excess of actual needs and is strongly influenced by new needs and is strongly influenced by new cultural trends and expectations and the cultural trends and expectations and the marketing practices of pharmaceutical marketing practices of pharmaceutical companies. These factors, together with a companies. These factors, together with a weak regulatory system and improper weak regulatory system and improper medical practice, may result in unjustified medical practice, may result in unjustified and excessive consumption. This has and excessive consumption. This has serious implications in terms of the develserious implications in terms of the development of dependence on drugs with addicopment of dependence on drugs with addictive potential and concerns about the way tive potential and concerns about the way that human behaviour is being controlled that human behaviour is being controlled by medicines. These concerns should not by medicines. These concerns should not be allowed to undermine the value of be allowed to undermine the value of modern psychotropic substances in alleviatmodern psychotropic substances in alleviating human pain and suffering. There is a ing human pain and suffering. There is a continuing challenge to ensure that such continuing challenge to ensure that such substances are available to all who need substances are available to all who need them, while reducing the potential for them, while reducing the potential for overconsumption where this exists. overconsumption where this exists. 
